Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles

Lee, Tsung-Hsien; Liu, Chung‐Hsien; Huang, Chun‐Chia; Hsieh, Kung-Chen; Lin, Pi-Mei; Lee, Maw‐Sheng

doi:10.1186/1477-7827-7-100

Cited by 82 publications

(67 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With regard to the ability to identify poor responder women, the analysis demonstrated the AMH is at least as efficient as AFC to predict a high ovarian response [49,50]. Various reports suggest a correlation between low AMH levels and poor ovarian response [28,[50][51][52].…”

Section: Discussionmentioning

confidence: 99%

Anti-mullerian hormone as a predictive marker for the selection of women for oocyte in vitro maturation treatment

Fadini

Comi

Renzini

et al. 2011

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose In oocyte in-vitro maturation (IVM) treatments, the chances to achieve a pregnancy are critically dependent on the retrieval of a suitable number of oocytes. In this study, we assessed the ability of circulating levels of anti-mullerian hormone (AMH) to identify normo-ovulatory women suitable for IVM treatment on the basis of the number of retrieved oocytes. Method Serum AMH was quantified in normo-ovulatory women younger than 39 years undergoing IVM treatment. After immature oocyte retrieval and IVM, maximum 3 mature oocytes were used for treatment and all resulting embryos were transferred, as established by law. From 177 cycles, 991 oocytes were recovered. Following IVM, 484 mature oocytes were obtained (50.1%). Results The overall pregnancy rate per embryo transfer was 16.6% (25/151) and the implantation rate was 10.9% (30/ 278). Linear regression and receiver operating characteristic (ROC) analyses were applied to identify independent variables and quantify a cut-off AMH value able to identify patients suitable for IVM treatment. An AMH value of 1.28 ng/ml was identified as a threshold for the prediction of the retrieval of at least 5 oocytes, with a sensitivity of 93.4% and a specificity of 33.8%. Positive and negative predictive values were 67.6% and 75.0%, respectively. Conclusions AMH can be adopted to identify women candidate for an IVM treatment from whom a suitable number of oocytes may be retrieved. This is of crucial significance during a non-stimulated cycle, in order to prevent an insufficient oocyte collection and rescue the treatment by implementing a conventional controlled ovarian stimulation.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-mullerian hormone as a predictive marker for the selection of women for oocyte in vitro maturation treatment

Fadini

Comi

Renzini

et al. 2011

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…Elevated plasma AMH levels are associated with better fertility rates (Lee et al 2009). Seifer et al (2002), the first authors reporting an association between serum AMH levels and ovarian response to gonadotrophin, showed that AMH levels were 2.5-fold higher in patients with at least 11 oocytes compared with those with six oocytes or fewer retrieved.…”

Section: Amh and Assisted Reproductive Technologymentioning

confidence: 99%

Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients

Bozza¹,

Puglisi²,

Lambertini³

et al. 2013

Endocrine-Related Cancer

View full text Add to dashboard Cite

Breast cancer is the most common invasive cancer in women of reproductive age. In young women, chemotherapy may induce amenorrhea: it is still uncertain how to assess menopausal status in these patients despite the importance of its definition for choosing appropriate endocrine treatment. In the development of sensitive biomarkers for fertility and ovarian reserve, anti-Mü llerian hormone (AMH) is considered a promising marker of ovarian reserve. The clearest data regarding a clinical use of AMH are related to the measurement of the ovarian pool in women who undergo IVF: the available data, also in breast cancer patients, seem to suggest that AMH measurement, before gonadotropin administration, can be a useful marker for the prediction of women at risk for poor-response or no response to ovarian stimulation. The utility of AMH as a potential marker of chemotherapy-induced ovarian follicular depletion and an early plasma marker of chemotherapy-induced gonadal damage has been evaluated both in young women after treatment for cancer in childhood and in young survivors of hematological malignancies and solid tumors. Several studies have demonstrated a potential utility of AMH, inhibin, or follicle-stimulating factor as biomarkers predicting infertility risk in breast cancer patients, but the studies conducted so far are not conclusive. Further studies are needed in order to define the regimen-specific action of chemotherapy on AMH levels, the percentage of post-treatment recovery of plasma levels of the hormone, and the relationship between menopausal status and AMH.

show abstract

“…10,11 From the present study, we conclude that age and AMH have negative correlation (r-0.266) ( Figure 1). …”

Section: -40mentioning

confidence: 86%

“…Patients were studied with respect to total number of oocytes, number of mature oocytes, duration of stimulation, total dose of gonadotropins, peak E2 levels, number of embryos and Grade A embryos. According to number of oocytes retreived, patients were divided into poor responders (<3 oocytes) normal responders (4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19) and hyperresponders (>20).…”

Section: Methodsmentioning

confidence: 99%

Evaluation of ovarian response prediction according to age and serum AMH levels in IVF cycles: a retrospective analysis

Pillai¹,

Mahabalshetti

2017

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

INTRODUCTIONThe accurate prediction of the response to ovarian stimulation is a valuable diagnostic step in the process of assisted reproduction. Increasing female literacy and employment have resulted in a clear rise in the age at which women conceive. As fertility starts to decline with advancing age more and more number of women are facing the problem of infertility and are seeking medical attention to overcome this problem. This decline in fertility is predominantly due to reduced ovarian reserve with increasing age. It has been shown that the rate of ovarian reserve decline varies considerably between individual women making it a challenge to design tests that estimate an individual's reproductive lifespan at a given age.1 A reliable marker for the age at which subfertility will occur would have great potential value as predictor of future reproductive lifespan. The ideal ABSTRACT Background: Increasing female literacy and employment have resulted in a clear rise in the age at which women conceive. As fertility starts to decline with advancing age more and more number of women are facing the problem of infertility and are seeking medical attention to overcome this problem. A number of ovarian reserve tests were developed to overcome this problem. Recent studies indicate that anti mullerian hormone is a promising marker for predicting ovarian reserve and pregnancy outcome. Methods: A retrospective study conducted at SAMAD IVF hospital, Trivandrum, Kerala. The aim of this study was to assess the influence of age on Anti-Mullerian Hormone (AMH) in ART (assisted reproductive technology) program outcomes and determine whether AMH levels and age predict the availability of total oocytes and MII oocytes retrieved and good quality of embryos. Ninety-six subjects in the age group of 25 to 40 years were included and underwent controlled ovarian stimulation (COS) and later intracytoplasmic sperm injection (ICSI) was performed. Results: In present study, it is seen that age and AMH (anti-mullerian hormone) have negative correlation. In accordance to AMH, total number of oocytes retrieved, MII oocytes, total number of embryos and grade A embryos were higher in AMH group (>5ng/ml). Total embryos for cryopreservation were lower in age group of 31-35yrs and 36-40yrs with least AMH value as compared to younger age group, good quality of embryos was higher in age group of 25-30yrs with 1.5-5 and >5 AMH group. Conclusions: Serum AMH is an important ovarian reserve test to predict response in ART cycles. Age is an independent marker in terms of quality of oocytes retrieved. We conclude that age and AMH have negative correlation. Hence, AMH can predict number of oocytes retrieved but age predicts quality of oocytes and embryos.

show abstract

Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles

Cited by 82 publications

References 38 publications

Anti-mullerian hormone as a predictive marker for the selection of women for oocyte in vitro maturation treatment

Anti-mullerian hormone as a predictive marker for the selection of women for oocyte in vitro maturation treatment

Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients

Evaluation of ovarian response prediction according to age and serum AMH levels in IVF cycles: a retrospective analysis

Contact Info

Product

Resources

About